BAD MEDICINE

An academic scientist, assigned to resolve a research dispute, instead uncovers conspiracies and murder in Cooper’s third medical thriller in a series.

As the story opens, Brad Parker, the chair of Boston Technological Institute’s department of integrated life sciences, has been coerced by a colleague into arbitrating a tenure case at the Maine Translational Research Institute. Carolyn Gelman, who’s almost universally despised by that institution’s faculty, claims that Mark Heller, a faculty favorite with ties to the pharmaceutical industry, is attempting to undermine her work. Both candidates do research into treating cancers that don’t respond to conventional methods. Cooper effectively guides readers through the hard science, letting narrator Brad explain Gelman’s lecture, for example, in order to keep readers engaged: “She focused on drugs that acted by inhibiting a class of enzymes called receptor tyrosine kinases, or RTKs….” An unknown interlocutor attempts to destroy Gelman’s research and poisons clinical trial patients, causing one to die. It turns out that the suspect works for someone with enough influence to get them a job as a lab assistant under Tom Carlson, a senior faculty member and one of Heller’s supporters. Moreover, it turns out that a suspect in FBI agent Karen Richmond’s case involving Russian mobsters happens to match the suspect’s body type. Such improbable connections between academia and organized crime will keep readers wondering if they see clues where they don’t exist or if they’re closing in on deeper intrigues. However, the novel sometimes falls short in other areas, such as dialogue, which occasionally lapses into the more dubious noir conventions, as when an adversary says to Brad, “You’re better than I thought you’d be. Or your FBI girlfriend is.” Still, the novel also offers quite a few swerves and red herrings to maintain tension throughout.

A noteworthy whodunit with unexpected plot twists.